Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Shenzhen Salubris Pharmaceuticals A (002294 CH)
Watchlist
34
Analysis
Health Care
•
China
Shenzhen Salubris Pharmaceuticals Co., Ltd. develops, manufactures, and distributes pharmaceutical and healthcare products such as tablets, capsules, injection formulations and active pharmaceutical ingredients.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Shandong Hi Speed Co Ltd A
•
21 May 2026 13:15
Quiddity Leaderboard CSI 300/500 Jun26: Final Expectations; ~US$10bn Collective One-Way Flows
The Net Inflow names are up +5.7% against the Net Outflow names since 8th May 2026. This is a continuation of the positive momentum observed in...
Janaghan Jeyakumar, CFA
Follow
315 Views
Share
bullish
•
Quantitative Analysis
•
17 May 2026 10:15
A-Share Margin Trading Weekly (May 15th): PING AN INSURANCE
We analyzed A-share margin trading positions report for the past week and highlighted PING AN INSURANCE (601318 CH), GUOTAI HAITONG SECURITIES...
Ke Yan, CFA, FRM
Follow
131 Views
Share
bullish
•
Thematic (Sector/Industry)
•
25 Oct 2016 12:40
Key Drivers of Asia's Healthcare Sector
From a demand perspective, Asia’s population is growing as is longevity. On the supply side, Asia’s number of doctors, nurses, hospitals and...
Singapore Exchange Ltd (SGX)
Follow
3.6k Views
Share
bearish
•
Thematic (Sector/Industry)
•
06 Oct 2016 21:27
Falling Fertility Adds to China's Population Woes
By allowing couples to have up to two children China hopes to reverse its likely population decline. But falling fertility and the pressures of...
Bixmoor
4.3k Views
Share
bearish
•
Thematic (Sector/Industry)
•
12 Sep 2016 23:18
Iran Shows China the Way on Population Expansion
Faced with dramatically falling birth rates, Iran has introduced a wide range of pro-natalist policies. In contrast, China has been half-hearted in...
Bixmoor
360 Views
Share
First
Previous
1
2
3
4
5
6
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x